

From: Do, Yu
Sent: Friday, January 15, 2016 12:09 PM
To: dmyers@malvernconsultinggroup.com
Subject: Information Request (Response Due by Friday, January 29, 2016): Original BLA, BL 125590/0, Immune Globulin Intravenous (RI-002), ADMA Biologics, Inc.

Importance: High

Dear Ms. Myers:

We are reviewing your original July 31, 2015 submission to BLA 125590/0 for Immune Globulin Intravenous (Human). We are providing the following comments and request additional information to continue our review:

(b) (4) Purity by (b) (4) Assay

1. With reference to SOP No. QC2161: Determination of Human IgG (b) (4) Purity in Aqueous Samples by (b) (4)

a. Please provide details of the sample identified by the Sample Name "Test" in Attachment 1 (page 10) of your SOP.

b. There is no mention of (b) (4) in your SOP No. QC2161. Please confirm that a (b) (4) can be used without (b) (4).

2. Regarding validation of the (b) (4) Purity by (b) (4) assay method:

a. You have determined concentrations of (b) (4) of a particular component and then plotted such concentrations against respective (b) (4) to demonstrate linearity of your method. You have determined (b) (4) of each component by dividing its (b) (4), which is constant at a particular protein concentration. Thus, you obtained the concentration of each component by (b) (4). Hence, this is circular.

Please provide plots of (b) (4) of each component against the total protein concentration of the drug product to demonstrate linearity of your method for each of the above components. Also, please provide correlation coefficient, slope, y-intercept, and distribution of residuals for each plot.

b. The (b) (4) are impurities present in your drug product. Please provide results to establish limits of quantitation (LOQ) of these components by your assay.

c. Please provide composition of the (b) (4) " (or (b) (4) and its (b) (4) obtained by your assay method to demonstrate that it does not have any (b) (4) that (b) (4) with any of the (b) (4) to demonstrate specificity of your method.

The review of this submission is ongoing and issues may be added, expanded upon, or modified as we continue to review this submission. Please submit your response as an amendment to this file by January 29, 2016, referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can

be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is July 30, 2016.

Please acknowledge receipt of this request and contact me at (240) 402-8343 or Yu.Do@fda.hhs.gov if you have any questions.

Sincerely,

Yu Do, M.S.
Regulatory Project Manager
FDA/OMPT/CBER/OBRR/RPMS
(240) 402-8343
yu.do@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."